NCT00230399

Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer

C-2424: Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (planned)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan, for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually, are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of these two drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination of capecitabine and irinotecan has a positive effect on metastatic colorectal cancer. Likewise, previous research in animals has shown that celecoxib, a drug approved for arthritis therapy, also has activity against this tumor type and may improve the anti-cancer activity of the combination of capecitabine and irinotecan.

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Celecoxib
DRUG	Capecitabine
DRUG	Irinotecan

Timeline

• Start date: 2003-06-01
• Primary completion: 2006-01-01
• Completion: 2008-03-01
• First posted: 2005-09-30
• Last updated: 2015-04-21

Locations

1 site across 1 country: United States